Edition:
India

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

78.75USD
23 Feb 2018
Change (% chg)

$1.56 (+2.02%)
Prev Close
$77.19
Open
$77.64
Day's High
$78.86
Day's Low
$77.64
Volume
1,617,212
Avg. Vol
1,149,595
52-wk High
$89.07
52-wk Low
$73.70

Latest Key Developments (Source: Significant Developments)

Eli Lilly And Co Q4 Non-GAAP Earnings Per Share $1.14
Wednesday, 31 Jan 2018 

Jan 31 (Reuters) - Eli Lilly And Co ::LILLY REPORTS STRONG FOURTH-QUARTER AND FULL-YEAR 2017 REVENUE GROWTH, INCREASES 2018 EPS GUIDANCE.Q4 NON-GAAP EARNINGS PER SHARE $1.14.Q4 EARNINGS PER SHARE VIEW $1.07 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 EARNINGS PER SHARE $4.39 TO $4.49 INCLUDING ITEMS.Q4 LOSS PER SHARE $1.58.FOR Q4 2017, ALIMTA GENERATED WORLDWIDE REVENUE OF $525.2 MILLION, WHICH DECREASED 3 PERCENT.ELI LILLY - RECORDED ESTIMATED CHARGE OF $1.9 BILLION IN QUARTER ASSOCIATED WITH U.S. TAX REFORM LEGISLATION, CHARGES ASSOCIATED WITH REDUCING COST STRUCTURE.QTRLY REVENUE $6,160.7 MILLION VERSUS $5,760.5 MILLION.Q4 REVENUE VIEW $5.93 BILLION -- THOMSON REUTERS I/B/E/S.SEES 2018 ADJUSTED EARNINGS PER SHARE $4.81 TO $4.91.QTRLY JARDIANCE SALES $143.2 MILLION VERSUS $76.1 MILLION.COMPANY STILL ANTICIPATES 2018 REVENUE BETWEEN $23.0 BILLION AND $23.5 BILLION.SAYS QTRLY CYMBALTA SALES $192.8 MILLION VERSUS $181.8 MILLION.FY2018 EARNINGS PER SHARE VIEW $4.68, REVENUE VIEW $23.21 BILLION -- THOMSON REUTERS I/B/E/S.QTRLY REPORTED LOSS PER SHARE $1.58.ELI LILLY - 2018 REV GROWTH EXPECTED TO BE DRIVEN BY NEW PRODUCTS INCLUDING TRULICITY, TALTZ, BASAGLAR, JARDIANCE, VERZENIO, CYRAMZA, OLUMIANT, LARTRUVO.ELI LILLY AND CO - DURING 2017, CO RECORDED INCOME TAX EXPENSE OF $2.402 BLN, WHICH INCLUDED AN ESTIMATED TAX CHARGE OF $1.914 BLN.  Full Article

Elanco Animal Health Announces U.S. FDA Approval Of Credelio To Treat Ticks And Fleas
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Eli Lilly And Co ::ELANCO ANIMAL HEALTH ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF CREDELIO® (LOTILANER) TO TREAT AND PROTECT AGAINST TICKS AND FLEAS.  Full Article

NSAV Subsidiary Signs Agreement With Eli Lilly
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Net Savings Link NSAV.PK::NSAV SUBSIDIARY SIGNS MAJOR AGREEMENT WITH ELI LILLY AND COMPANY.NET SAVINGS LINK SAYS VSRI WILL PROVIDE ELI LILLY WITH ASSESSMENT OF CVD AMONG NEWLY DIAGNOSED DIABETES PATIENTS AT INCREASED RISK OF CVD IN CHINA.  Full Article

Lilly Announces 2018 Financial Guidance, Enhances Outlook Through 2020
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Eli Lilly And Co ::LILLY ANNOUNCES 2018 FINANCIAL GUIDANCE AND ENHANCES OUTLOOK THROUGH 2020.SEES FY 2018 REVENUE $23 BILLION TO $23.5 BILLION.SEES FY 2017 EARNINGS PER SHARE $1.56 TO $1.66.SEES FY 2018 EARNINGS PER SHARE $4.24 TO $4.34.- REAFFIRMED ITS EXPECTATION OF AT LEAST 5 PERCENT AVERAGE ANNUAL REVENUE GROWTH FROM 2015 TO 2020, ON A CONSTANT CURRENCY BASIS.FY2017 EARNINGS PER SHARE VIEW $4.21 -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $4.64, REVENUE VIEW $23.07 BILLION -- THOMSON REUTERS I/B/E/S.ELI LILLY - EXPECT OPERATING MARGIN AS PERCENT OF REVENUE TO BE AT LEAST 30 PERCENT IN 2020, EXCLUDING EFFECT OF FOREX ON INTERNATIONAL INVENTORIES SOLD.- ON A NON-GAAP BASIS, REAFFIRMED 2017 EPS TO BE IN RANGE OF $4.15 TO $4.25.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $4.60 TO $4.70.- SEES 2018 CAPITAL EXPENDITURES ABOUT $1.2 BILLION.ELI LILLY SEES 2018 REVENUE GROWTH DRIVEN BY NEW PRODUCTS INCLUDING TRULICITY, BASAGLAR, JARDIANCE, VERZENIO, OLUMIANT.ELI LILLY - REVISION TO 2017 EARNINGS PER SHARE OUTLOOK IS DUE TO CHANGES IN ESTIMATES RELATED TO ASSET IMPAIRMENT, RESTRUCTURING, OTHER SPECIAL CHARGES.  Full Article

Lilly Announces 8 Percent Dividend Increase
Tuesday, 12 Dec 2017 

Eli Lilly And Co ::LILLY ANNOUNCES 8 PERCENT DIVIDEND INCREASE.ELI LILLY AND CO - DIVIDEND FOR Q1 WILL BE $0.5625 PER SHARE ON OUTSTANDING COMMON STOCK.  Full Article

FDA Accepts Biologics License Application (BLA) To Review Galcanezumab For The Prevention Of Migraine In Adults
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Eli Lilly And Co ::FDA ACCEPTS BIOLOGICS LICENSE APPLICATION (BLA) TO REVIEW GALCANEZUMAB FOR THE PREVENTION OF MIGRAINE IN ADULTS.ELI LILLY AND CO - ‍FDA ACCEPTED BLA TO REVIEW GALCANEZUMAB FOR PREVENTION OF MIGRAINE IN ADULTS​.  Full Article

Lilly's Cyramza meets Primary Endpoint in gastric cancer study
Saturday, 9 Dec 2017 

Dec 8 (Reuters) - Eli Lilly And Co ::LILLY REPORTS TOP-LINE RESULTS FROM CYRAMZA® (RAMUCIRUMAB) PHASE 3 STUDY IN FIRST-LINE ADVANCED GASTRIC CANCER.ELI LILLY AND CO - TRIAL MET ITS PRIMARY ENDPOINT.ELI LILLY AND CO - PHASE 3 RAINFALL STUDY DID NOT IMPROVE OVERALL SURVIVAL (OS), A SECONDARY ENDPOINT.ELI LILLY - SAFETY PROFILE OBSERVED IN RAINFALL STUDY WAS CONSISTENT WITH THAT PREVIOUSLY OBSERVED FOR RAMUCIRUMAB.ELI LILLY AND CO - DOES NOT INTEND TO SEEK REGULATORY APPROVAL BASED ON RESULTS OF RAINFALL STUDY.ELI LILLY AND CO - OUTCOME OF RAINFALL DOES NOT HAVE ANY IMPACT ON CURRENT RAMUCIRUMAB APPROVALS.ELI LILLY AND CO - TWO OTHER ONGOING PHASE 3 STUDIES OF RAMUCIRUMAB ARE ONGOING, WITH EXPECTED DATA READOUTS IN 2018.  Full Article

Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Juno Therapeutics Inc ::JUNO THERAPEUTICS SIGNS LICENSING AGREEMENTS WITH LILLY, ONCOTRACKER, AND FRED HUTCHINSON CANCER RESEARCH CENTER TO ADVANCE ITS BCMA-DIRECTED ENGINEERED T CELL PROGRAM IN MULTIPLE MYELOMA WITH GAMMA SECRETASE INHIBITION.JUNO THERAPEUTICS - THREE LICENSE DEALS TO ADVANCE PROGRAM IN MULTIPLE MYELOMA USING GAMMA SECRETASE INHIBITORS WITH BCMA-DIRECTED CAR T CELLS.JUNO THERAPEUTICS INC - THROUGH ITS AGREEMENT WITH ELI LILLY AND COMPANY, JUNO WILL ACQUIRE A LICENSE TO GSI KNOWN AS LY3039478.JUNO THERAPEUTICS- CO TO ALSO GAIN RIGHTS TO INTELLECTUAL PROPERTY WITHIN FIELD OF COMBINATIONS OF GSIS, BCMA-DIRECTED ENGINEERED T CELLS IN OTHER DEALS.JUNO THERAPEUTICS INC - NO OTHER TERMS FROM THESE THREE TRANSACTIONS WERE DISCLOSED.  Full Article

Novo Nordisk expects to launch new diabetes drug in Japan during H1 2018
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - NOVO NORDISK A/S CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN MADE FOLLOWING COMMENTS DURING AN INVESTOR CALL FOLLOWING U.S. APPROVAL OF DIABETES DRUG OZEMPIC::STILL EXPECTS TO LAUNCH OZEMPIC DIABETES DRUG IN JAPAN DURING THE FIRST HALF OF NEXT YEAR."WHEN IT COMES TO THE JAPANESE SITUATION WE ARE STILL EXPECTING TO MEET UP WITH THE COMMITTEE DURING THE COURSE OF JANUARY AND THEN BE ABLE TO WRAP UP THE LABEL, SO WE ARE EXPECTING ... TO LAUNCH DURING THE COURSE OF THE FIRST OF HALF OF NEXT YEAR ALSO IN JAPAN"."IN EUROPE WE SHOULD HOPE THAT THE ENDORSEMENT IS GIVEN BY THE CHMP (COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE) DURING THE MONTH OF DECEMBER".THE U.S. FOOD AND DRUG ADMINISTRATION ON TUESDAY APPROVED NOVO'S DIABETES DRUG OZEMPIC, SETTING THE STAGE FOR A HEATED BATTLE WITH ELI LILLY & CO'S <<>> TRULICITY nL1N1O51MY.  Full Article

Eli Lilly initiates clinical trial to evaluate its automated insulin delivery system
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Eli Lilly And Co ::LILLY INITIATES CLINICAL TRIAL TO EVALUATE THE FUNCTIONALITY AND SAFETY OF ITS AUTOMATED INSULIN DELIVERY SYSTEM.  Full Article

BRIEF-Eli Lilly Says CEO David Ricks' FY 2017 Total Compensation Was $15.8 Mln

* ELI LILLY AND CO SAYS CHAIRMAN AND CEO DAVID RICKS' FY 2017 TOTAL COMPENSATION WAS $15.8 MILLION